Showing 71-80 of 9661 results for "".
- TRACE Study: Delayed Responses to Tralokinumab Observed in Atopic Dermatitishttps://practicaldermatology.com/news/trace-study-delayed-responses-to-tralokinumab-observed-in-atopic-dermatitis/2488698/More than three-quarters of patients with atopic dermatitis (AD) who had not achieved a composite clinical response to tralokinumab after 3 months met response criteria by month 12, according to findings from the prospective, international TRACE study presented at the 2026 European Academy of Der
- Facial Volume Loss, Hair Changes Among GLP-1 Dermatologic Concerns: Analysishttps://practicaldermatology.com/news/facial-volume-loss-hair-changes-among-glp-1-dermatologic-concerns-analysis/2488695/A new narrative review published in Clinics in Dermatology took a closer look at the cutaneous effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), including facial volume loss, hair changes, skin laxity, and potential benefits in inflammatory skin diseases. Researcher
- Deuruxolitinib Hair Regrowth Responses Similar With or Without Nail Involvement in Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-hair-regrowth-responses-similar-with-or-without-nail-involvement-in-severe-alopecia-areata/2488685/Baseline nail involvement was not associated with a statistically significant difference in scalp hair regrowth among adults with severe alopecia areata receiving deuruxolitinib 8 mg twice daily, according to a pooled post hoc analysis of the phase 3 THRIVE-AA1 and THRIVE-AA2 trials presented at
- Tapinarof Improves Pediatric Sleep and Family Sleep Impact in ADORING Trial Analysishttps://practicaldermatology.com/news/tapinarof-improves-pediatric-sleep-and-family-sleep-impact-in-adoring-trial-analysis/2488684/Once-daily tapinarof cream 1% was associated with greater improvements in sleep-related symptoms than vehicle among children with atopic dermatitis (AD), according to a post hoc analysis of the phase 3 ADORING 1 and ADORING 2 trials. Mark Boguniewicz, MD, and colleagues evaluated pooled da
- Survey Finds Topical Corticosteroid Concerns Affect Use and Patient-Clinician Discussionshttps://practicaldermatology.com/news/survey-finds-topical-corticosteroid-concerns-affect-use-and-patient-clinician-discussions/2488682/Concerns about adverse effects were associated with less frequent use of prescribed topical corticosteroids (TCS) among adults and caregivers of children with inflammatory skin conditions, according to survey findings presented at the 2026 Fall Clinical Dermatology Conference. Tina Bhutani
- Difamilast Ointment Shows Week 4 Benefits in Pediatric and Adult Atopic Dermatitis Trialshttps://practicaldermatology.com/news/difamilast-ointment-shows-week-4-benefits-in-pediatric-and-adult-atopic-dermatitis-trials/2488681/Difamilast 1% ointment was associated with higher rates of Investigator’s Global Assessment (IGA) success than vehicle at week 4 in separate phase 3 studies involving adults and children with atopic dermatitis (AD), according to an integrated review presented at the 2026 Fall Clinical Dermatology
- Barzolvolimab Responses Persist After Treatment in Selected Chronic Urticaria Patientshttps://practicaldermatology.com/news/barzolvolimab-responses-persist-after-treatment-in-selected-chronic-urticaria-patients/2488679/Nearly 7 in 10 evaluable patients with antihistamine-refractory chronic spontaneous urticaria (CSU) who achieved well-controlled disease after a year of barzolvolimab maintained control 24 weeks later, according to a post hoc analysis of a phase 2 trial presented at the 2026 Fall Clinical Dermato
- Pediatric Nemolizumab Study Reports Improvements in Atopic Dermatitis Through 52 Weekshttps://practicaldermatology.com/news/pediatric-nemolizumab-study-reports-improvements-in-atopic-dermatitis-through-52-weeks/2488676/Weight-based nemolizumab administered with topical therapy was associated with improvements in skin lesions and itch in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to phase 2 findings presented at the 2026 Fall Clinical Dermatology Conference. Lawr
- GLP-1 Medication Use Shows No Apparent Impact on Icotrokinra Outcomes in Phase 3 Psoriasis Analysishttps://practicaldermatology.com/news/glp-1-medication-use-shows-no-apparent-impact-on-icotrokinra-outcomes-in-phase-3-psoriasis-analysis/2488675/Concomitant use of glucagon-like peptide-1 (GLP-1)–based medications was not associated with an apparent difference in icotrokinra efficacy, safety, or pharmacokinetics among patients with plaque psoriasis, according to pooled post hoc analyses of the phase 3 ICONIC clinical trial program present
- Comparison Examines GEP Performance Against Melanoma SLNB Risk Thresholdshttps://practicaldermatology.com/news/comparison-examines-gep-performance-against-melanoma-slnb-risk-thresholds/2488674/A comparison of two prospective studies evaluating gene expression profiling (GEP) tests combined with clinicopathologic factors found differences in their ability to identify patients with cutaneous melanoma at low risk for sentinel lymph node (SLN) positivity.1